A novel preformed expanded polytetrafluoroethylene cordal implantation device conferred positive outcomes in patients undergoing surgical mitral valve repair, in a first-in-human study.
Eleven patients (mean age, 65 years) with severe mitral regurgitation and posterior leaflet prolapse to undergo mitral valve repair had the first results reported in Circulation with the use of minimally invasive device (Harpoon TSD-5, Harpoon Medical).
The outcomes of interest were reduction in mitral regurgitation and effect on left ventricular and left anterior reverse remodeling at 1 month.
The procedural success rate was 100%, James S. Gammie, MD, from the division of cardiac surgery at University of Maryland School of Medicine, and colleagues wrote.
Of the four patients followed to 6 months, reduction in mitral regurgitation was sustained in three, Gammie and colleagues wrote. One patient needed reoperation for recurrent mitral regurgitation.
The study was funded by Harpoon Medical. Gammie and three other researchers report ownership of stock or stock options in Harpoon Medical.
Source Healio